FSGS

Possible Tissue Injury Predictor in Transplant Recipients Found

Possible Tissue Injury Predictor in Transplant Recipients Found

Researchers may have found a predictor for focal segmental glomerulosclerosis (FSGS) in kidney transplant recipients.

FSGS: Talking Points for the Practicing Nephrologist

Distinguishing primary from secondary focal segmental glomerulosclerosis is crucial because the treatment approaches and therapeutic goals differ.

FSGS May Respond to Arthritis Drug

By

In a small study, abatacept induced partial or complete remission of focal segmental glomerulosclerosis.

In Search of Kidney-Saving Treatments for FSGS: Interview with Fernando Fervenza, MD

In Search of Kidney-Saving Treatments for FSGS: Interview with Fernando Fervenza, MD

By

The scar tissue that forms on sections of some glomeruli in FSGS will lead to kidney failure if left untreated.

Glomerular Diseases: Updates on Pathogenesis and Treatment

Glomerular Diseases: Updates on Pathogenesis and Treatment

By By

A number of new diagnostic and therapeutic tools have emerged in the field of glomerular diseases.

Black Race Worsens Transplant Outcomes

By

Black race is associated with worse renal transplant outcomes among patients with lupus nephritis and focal segmental glomerulosclerosis (FSGS), according to two studies presented at Kidney Week, the annual meeting of the American Society of Nephrology.

Black Transplant Patients with FSGS Are At Higher Risk

By

PHILADELPHIA—Among kidney transplant recipients with focal segmental glomerulosclerosis (FSGS), African-Americans (AA) have a greater prevalence of risk factors for allograft failure compared with other races, according to findings presented at Kidney Week 2011.

Male Gender, Older Age Raise RCC Risk in Long-Term Dialysis Patients

By

Development renal cell carcinoma (RCC) in patients on long-term dialysis is associated with older age, male gender, acquired renal cysts, and end-stage renal disease.

Steroids May Harm Athletes' Kidneys

By

Serious renal damage is a possible consequence of long-term abuse of anabolic steroids, data show .

Why African Americans Have More ESRD

By

Reseachers have identified, for the first time, gene variations that explain the increased burden of kidney diseases among African Americans.

Mycophenolate Mofetil Works As Well As Standard Therapy

By

Six months of mycophenolate mofetil (MMF) treatment is as effective in the short term as conventional therapy for primary treatment of membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), a pilot study in India found.

MMF Similar to Conventional Therapies for MN, FSGS

By

A six-month course of treatment with mycophenolate mofetil (MMF) is as effective as conventional therapies for treating membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), according to a pilot study conducted in India.

Diagnosing, Treating FSGS: An Update

Focal segmental glomerulosclerosis (FSGS) is not a single disease but a histologic pattern of renal damage that initially affects the glomerulus and its tubulointerstitium.

Study Reveals Epidemiology of Glomerulopathies in Brazil

Five-year data gathered by the Paulista Registry of Glomerulopathies in São Paulo, Brazil, shows that focal and segmental glomerulosclerosis is the most common primary glomerular disease, followed by membranous nephropathy and IgA nephropathy.

Sign Up for Free e-newsletters